Aclaris Therapeutics (ACRS) Misses Q4 EPS by 1c

Aclaris Therapeutics (NASDAQ: ACRS) reported Q4 EPS of ($0.16), $0.01 worse than the analyst estimate of ($0.15). Revenue for the quarter came in at $1.3 million versus the consensus estimate of $1.94 million.

For earnings history and earnings-related data on Aclaris Therapeutics (ACRS) click here.

You May Also Be Interested In

• Iran's foreign ministry spokesperson: no talks with the U.S. in coming days
• Carlisle Made Unsolicited Offers for Rival Owens Corning - WSJ
• Kansas City Capital Downgrades Apogee Enterprises (APOG) to Perform